Business
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer
Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignanciesCAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead cell therapy cand
About this update from Ernexa Therapeutics Inc.
[{"type":"image","alt":"Ernexa Therapeutics Inc.","displaySize":"","headline":null,"caption":"Ernexa Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":166,"url":"https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_oDYUSflXSfeQ8zZ8t_rmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/5060d0692cdc61118022bf7e5069f69d","width":300,"height":166}},"lazy":false},{"type":"text","content":"Positive results of ERNA-101 in ovarian cancer models demonstrated promising survival benefit and immune activation, underscoring the potential for broad oncology applications, including hematologic malignancies","length":211,"tagName":"p"},{"type":"text","content":"CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancer and autoimmune disease, today announced the presentation of new preclinical data on its lead cell therapy candidate, ERNA-101, at the American Society of Hematology (ASH) Annual Meeting. The data demonstrated that its proprietary cell therapy platform can rapidly and durably reprogram immunosuppressive tumor microenvironments (TMEs) into immune-active, pro-inflammatory states to combat cancer.","length":575,"tagName":"p"},{"type":"text","content":"The platform engineers induced pluripotent stem cells (iPSCs) and transforms them into induced mesenchymal stem cells (iMSCs). The preclinical findings underscore the platform’s potential to overcome resistance in both solid tumors and hematologic malignancies and highlight a scalable, off-the-shelf approach to local cytokine delivery.","length":337,"tagName":"p"},{"type":"text","content":"The abstract titled, ”Gene-modified iPSC-derived MSCs convert immunosuppressive tumor microenvironments (TMEs) into distinct pro-inflammatory TMEs,” was recently presented in an oral presentation by Michael Andreeff, M.D., Ph.D., Professor of Medicine, Department of Leukemia, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center and lead author on the study.","length":387,"tagName":"p"},{"type":"text","content":"“These data represent an important validation of our platform and reinforce our belief that iPSC...